hotspot -WSS

hotspot

author：comprehensive 2025-08-25 16:35:22 - browse：8

Powdered ibogaine against a white background. — Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Study: AI not yet building 'n

hotspot

WSS

Large hospital system sues Multiplan for low

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

H5N1 communication has been strictly for the birds

GOP presidential candidates start declaring their loyalty

The history of OxyContin, told through Purdue Pharma documents

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

explore

hotspot

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

An innovative path out of biotech’s “valley of death”

Anesthesiologist group: stop taking Ozempic before surgery

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

How one medical school became remarkably diverse

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

Apple is now the first public company to be valued at $3 trillion

The history of OxyContin, told through Purdue Pharma documents

Wildfire smoke exposes gaps in outdoor worker protections

After gene therapy, two congenitally deaf children hear for the first time

knowledge

First recipient of genetically engineered pig kidney has died

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

Genentech weighs delaying cancer therapy after drug pricing law

Genentech weighs delaying cancer therapy after drug pricing law

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Timeline: Special counsel's investigation into Trump's handling of classified documents

focus

hotspot

leisure time

focus